Literature DB >> 32629772

Vasopressors and Inotropes in Acute Myocardial Infarction Related Cardiogenic Shock: A Systematic Review and Meta-Analysis.

Mina Karami1, Veemal V Hemradj2, Dagmar M Ouweneel1, Corstiaan A den Uil3, Jacqueline Limpens4, Luuk C Otterspoor5, Alexander P Vlaar6, Wim K Lagrand6, José P S Henriques1.   

Abstract

Vasopressors and inotropes are routinely used in acute myocardial infarction (AMI) related cardiogenic shock (CS) to improve hemodynamics. We aimed to investigate the effect of routinely used vasopressor and inotropes on mortality in AMI related CS. A systematic search of MEDLINE, EMBASE and CENTRAL was performed up to 20 February 2019. Randomized and observational studies reporting mortality of AMI related CS patients were included. At least one group should have received the vasopressor/inotrope compared with a control group not exposed to the vasopressor/inotrope. Exclusion criteria were case reports, correspondence and studies including only post-cardiac surgery patients. In total, 19 studies (6 RCTs) were included, comprising 2478 CS patients. The overall quality of evidence was graded low. Treatment with adrenaline, noradrenaline, vasopressin, milrinone, levosimendan, dobutamine or dopamine was not associated with a difference in mortality between therapy and control group. We found a trend toward better outcome with levosimendan, compared with control (RR 0.69, 95% CI 0.47-1.00). In conclusion, we found insufficient evidence that routinely used vasopressors and inotropes are associated with reduced mortality in patients with AMI related CS. Considering the limited evidence, this study emphasizes the need for randomized trials with appropriate endpoints and methodology.

Entities:  

Keywords:  cardiogenic shock; inotrope; low cardiac output; myocardial infarction; review; shock; vasopressor

Year:  2020        PMID: 32629772     DOI: 10.3390/jcm9072051

Source DB:  PubMed          Journal:  J Clin Med        ISSN: 2077-0383            Impact factor:   4.241


  8 in total

1.  The clinical efficacy of integrated care in combination with vasopressin for cardiogenic shock induced by acute myocardial infarction: A randomized controlled study protocol.

Authors:  Ling Xu; Qunxing Li; Delu Yin; Guangyu Song; Hongyan Wu
Journal:  Medicine (Baltimore)       Date:  2022-04-29       Impact factor: 1.817

Review 2.  Inotropic support in cardiogenic shock: who leads the battle, milrinone or dobutamine?

Authors:  Ivan David Lozada Martinez; Andrea Juliana Bayona-Gamboa; Duvier Fabián Meza-Fandiño; Omar Andrés Paz-Echeverry; Ángela María Ávila-Bonilla; Mario Javier Paz-Echeverry; Frank Jaider Pineda-Trujillo; Gina Paola Rodríguez-García; Jaime Enrique Covaleda-Vargas; Alexis Rafael Narvaez-Rojas
Journal:  Ann Med Surg (Lond)       Date:  2022-09-22

3.  Vasoactive pharmacologic therapy in cardiogenic shock: a critical review.

Authors:  Rasha Kaddoura; Amr Elmoheen; Ehab Badawy; Mahmoud F Eltawagny; Mohamed A Seif; Khalid Bashir; Amar M Salam
Journal:  J Drug Assess       Date:  2021-07-20

4.  Cardioprotective shock management: monitoring and supportive therapies.

Authors:  David Schibilsky; Clement Delmas; Laurent Bonello; Patrick Hunziker
Journal:  Eur Heart J Suppl       Date:  2021-03-27       Impact factor: 1.803

Review 5.  A Clinical Update on Vasoactive Medication in the Management of Cardiogenic Shock.

Authors:  Aditi Shankar; Gayathri Gurumurthy; Lakshmi Sridharan; Divya Gupta; William J Nicholson; Wissam A Jaber; Saraschandra Vallabhajosyula
Journal:  Clin Med Insights Cardiol       Date:  2022-02-07

Review 6.  Evolving Presentation of Cardiogenic Shock: A Review of the Medical Literature and Current Practices.

Authors:  Neal Olarte; Nina Thakkar Rivera; Luanda Grazette
Journal:  Cardiol Ther       Date:  2022-08-07

7.  Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome.

Authors:  Konstantin Uhlig; Ljupcho Efremov; Jörn Tongers; Stefan Frantz; Rafael Mikolajczyk; Daniel Sedding; Julia Schumann
Journal:  Cochrane Database Syst Rev       Date:  2020-11-05

Review 8.  Recent Advances in the Therapeutic Efficacy of Artesunate.

Authors:  Ngonidzashe Ruwizhi; Rejoice Bethusile Maseko; Blessing Atim Aderibigbe
Journal:  Pharmaceutics       Date:  2022-02-25       Impact factor: 6.321

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.